

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Gino Kim IN

eRA COMMONS USER NAME (credential, e.g., agency login): ginokin11

POSITION TITLE: Assistant Professor of Medicine and Dermatology

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Emory University	BS	05/2002	Biology/Economics(m)
Emory University, Rollins School of Public Health	MPH	05/2006	Environmental / Occupational Health
Ross University	MD	05/2010	Medicine
State University of New York, Downstate College of Medicine	Internship	06/2011	Internal Medicine
State University of New York, Downstate College of Medicine	Residency	06/2013	Internal Medicine
University of Southern California, Keck School of Medicine	Fellowship	06/2016	Hematology / Oncology

Personal Statement

I am a physician-scientist with a background in solid tumor medical oncology, with a focus on the development and conduct of clinical trials to further the use of novel oncology therapeutics and combinations. Within solid tumor oncology, my area of expertise is the management of cutaneous tumors, including melanoma and non-melanoma skin cancers. As lead melanoma PI at our institution, I oversee the multi-disciplinary melanoma and skin cancer program and portfolio of therapeutic clinical trials for all cutaneous malignancies, including investigator-initiated studies and industry sponsored studies, as well as those conducted in coordination with cooperative groups, including those under the Southwest Oncology Group (SWOG), California Cancer Consortium (NCI-CTEP), Alliance and the ACCRU Network. In addition to my role as a clinical trialist, I have a translational research interested in rare cutaneous malignancies (Merkel cell carcinoma, extramammary Paget's disease, sweat gland tumors), as well as rare / aggressive subtypes of common cutaneous malignancies (acral lentiginous melanoma, metastatic cutaneous squamous cell carcinoma, metastatic basal cell carcinoma).

Positions and Employment

2010-2011 Intern, Internal Medicine, SUNY Downstate Medical Center, Brooklyn, NY

2011-2013 Residency, Internal Medicine, SUNY Downstate Medical Center, Brooklyn, NY

2012-2013 Postdoctoral Researcher, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY

2013-2016 Fellow, Hematology and Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA

2016-Present Assistant Professor of Clinical Medicine, Division of Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA

2016-Present Staff Attending, Division of Oncology, Los Angeles County Medical Center, Los Angeles, CA

2016-Present Staff Attending, Hematology/Oncology, Huntington Hospital, Pasadena, CA

2017-Present Assistant Professor of Dermatology, University of Southern California, Keck School of Medicine, Los Angeles CA

2020-Present Staff Attending, Hematology/Oncology, Verdugo Hills Hospital, Glendale CA

Honors

2015-2016 Chief Oncology Fellow, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA

2020-2021 L.A.'s Top Doctor – Oncology, Los Angeles Magazine

Contributions to Science

1. Clinical trials for the treatment of melanoma and other cutaneous malignancies. Ours is a large National Cancer Institute-designated cancer center that is part of a university hospital system, the University of Southern California Health Sciences Center, and including a public county health net hospital, the Los Angeles County Medical Center, all of which are located in Los Angeles, where incidence rates of melanoma are among the highest in the world. In this setting, we are actively involved in the conduct of clinical trials, not only for the management of advanced/metastatic melanoma, but other malignancies as well. We have been active contributors to a number of investigator initiated, cooperative group and industry sponsored studies that employ novel immunotherapy agents, including checkpoint inhibitors, autologous cell therapy, and also targeted therapies and intratumoral agents.

Sundararajan S, McBride A, Tarhini A, **In GK**, Kendra KL, Lutzky J, Carson WE, Roe D, Jeter J. A Phase I/II Study of Pembrolizumab and Imatinib in Patients with Locally Advanced / Metastatic Melanoma with c-KIT Mutation or Amplification. *Pigment Cell Melanoma Res.* 2018;31:125-230.

Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, **In GK**, Wang P, Liu G, Collichio FA, Googe PB, Carson CC, McKinnon K, Wang HH, Nikolaishvilli-Feinberg N, Ivanova A, Arrowood CC, Garrett-Mead N, Conway KC, Edmiston SN, Ollila DW, Serody JS, Thomas NE, Ivy SP, Agrawal L, Dees EC, Abbruzzese JL. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). *Melanoma Res.* 2021 Apr 1;31(2):162-172. doi: 10.1097/CMR.0000000000000726. PMID: 33661190

Butler MO, Robert C, Negrier S, **In GK**, Walker J, Krajsova I, Atkinson V, Hansson J, Kapiteijn EH, Loquai C, Shaw H, Cheng T, Mansard S, Grob JJ, Guidoboni M, Mehta M, Ascierto PA, Diab A. ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy. *J Clin Oncol.* 2019 ASCO Annual Meeting. DOI: 10.1200/JCO.2019.37.15_suppl.TPS9599

Silk AW, LeBouef N, Chandra S, **In GK**, Burgess M, Davar D, Hyngstrom J, Voorhies B, Thakuria M, Moore D, Chen H, Zloza A, Mehnert J. Interim Analysis of a Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Merkel Cell Carcinoma (NCI #10057). Abstract Submission to 1st International Symposium on Merkel Cell Carcinoma, 2019.

Trodello C, Higgins S*, Ahadiat O, Ragab O, **In G**, Hawkins M, Wysong A. Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. *Dermatologic Surgery.* 2019 Feb;45(2):254-267. PMID: 30672860

In GK, Vaidya P*, Filkins A*, Hermel DJ*, King KG, Ragab O, Tseng WW, Swanson M, Kokot N, Lang JE, Menendez L, DeClerck B, Kim G, Hu JC, Terando A, Jadvar H, Ricker C, Miller KA, Peng DH, Wysong A. PD-1 Inhibition Therapy for Advanced Cutaneous Squamous Cell Carcinoma: a Retrospective Analysis from the University of Southern California. *J Cancer Res Clin Oncol.* 2020 Nov 18. Doi: 10.1007/s00432-020-03458-6. PMID: 33210210

Thomas SS, **In GK**, Doger B, Haeffliger S, Martin-Liberal J, Goldberg Z, Cacovean A, Fiaz R, Chen G, Jagasia MH, Finckenstein FG, Fardis M, Jimeno A. Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma. Poster Presentation at 2021 ASCO Annual Meeting. *J Clin Oncol.*

2. Investigation of disparities affecting patients with cutaneous and solid tumor malignancies. Our multi-disciplinary research team seeks to define the epidemiological, biological, clinical and social disparities affecting patients with cutaneous tumors and other malignancies. Our work has particularly focused on disparities affecting three groups of patients: patients with rare cutaneous malignancies, patients with rare presentations/subtypes of cutaneous malignancies, or understudied populations who suffer from cutaneous malignancies.

In GK, Yang D, Thomas JS*, Pham A*, Basu A*, Mehta AA*, Miller KA, Cockburn MG, Hu J. Frequency and Outcomes of Melanoma Subtypes in a Diverse Population: The Los Angeles County – University of Southern California (LAC-USC) Medical Center Experience. *J Clin Oncol*. DOI: 10.1200/JCO.2017.35.15_suppl.e21063

Miller KA, Pham A*, Thomas JS*, Cockburn MG, Freyer DR, Hu J, Milam J, Wojcik K, **In GK****. Clinical Characteristics of Melanoma in an Ethnically Diverse Population of Adolescents and Young Adults. *J Clin Oncol*. DOI: 10.1200/JCO.2017.35.15_suppl.e21043

Wojcik KY, **In GK**, Navid F. Melanoma. *Cancer in Los Angeles County: Survival Among Adolescents and Young Adults 1988-2014*. Los Angeles Cancer Surveillance Program, University of Southern California. 102-106, 2017.

D'Souza A, Brooks C, **In G**, Raymond V, Lanman R, Nieva J. Impact of Liquid Biopsy on the Treatment of Low-Income Lung Cancer Patients. *J Thorac Oncol*. Volume 12(11), Supplement 2, Page S2027. November 2017.

Chaddha U*, Maehara D*, Lin S*, **In G**, Chang CF, Balekian A. Effect of Language and Ethnicity on Interval From Diagnosis to Treatment in Non-Small Cell Lung Cancer Patients at a Public and a Private Hospital. *Chest*. Volume 152(4), Suppl, Page A620. CHEST 2017 Meeting.

Miller KA, **In GK**, Jiang SY, Ahadiat O, Higgins S*, Wysong A, Cockburn MG. Skin Cancer Prevention Among Hispanics: a Review of the Literature. *Curr Derm Rep*. 2017 Sept;6(3):186-195. DOI: 10.1007/s13671-017-0191-8

In GK, Chow L, Lara K, Ragab O, Andrade J, Mehta A, Tseng W, Hu JS. Clinical Experience with Acral Melanoma at the University of Southern California. *Pigment Cell Melanoma Res*. Poster Presentation, SMR Congress 2018

Vaidya P*, Samaan J*, Ghanshani S*, Maw TT, **In GK****. Incidences and Outcomes of Secondary Cutaneous Malignancies Among Renal Transplant Recipients. *J Invest Dermatol*. Montagna Symposium on the Biology of Skin 2018.

Jeong AR*, Hu J, Higgins S*, Wysong A, **In GK****. Clinical Experience with Dermatofibrosarcoma Protuberans (DFSP) in a Diverse Ethnic Population. *J Clin Oncol*. DOI: 10.1200/JCO.2018.36.15_suppl.e23531

Adler BL, Smogorzewski J, Sierro T, Shauly O, Osipchuk D, Miller M, Mert M, Fong MW, Ganesh S, Han H, **In GK**, Maw TT, Smogorzewski M, Hu J, Ngo B, Lee D, Ahronowitz I. Skin cancer and dermatoses in a majority Hispanic population of solid organ transplant recipients. *J Am Acad Dermatol*. 2019 Aug 7;S0190-9622(19)32492-2. PMID: 31400454

Miller KA, Wojcik KY, Cockburn MG, **In GK**, Hamilton AS, Milam JE. Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study. *Pediatr Blood Cancer*. 2019 Nov 27:e28090. DOI: 10.1002/pbc.28090. Published online November 27, 2019. PMID: 31774240

Wong A, Truong T, Vaidya P, In G, Maw TT. Secondary Malignancy in Kidney Transplant Recipients: University of Southern California Experience. *J Am Soc Nephrol*. 2020. Abstract, American Society of Nephrology, 2020 Kidney Week, Annual Meeting.

Rabi S, Syder N, Ragab O, **In G**, Hu JC. Rapidly Progressive Porocarcinoma of the Ear and Multidisciplinary Approach to Management. *Dermatol Surg*. Published online March 4, 2020. PMID: 32141925

Lu JE, Chang JR, Berry JL, **In GK**, Zhang-Nunes, S. Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. *Int Ophthalmol Clin*. 2020 Spring;60(2):77-89. PMID: 32205655

Wilhite AM, Wu S, Xiu J, Korn M, Phung T, Herzog TJ, **In GK**, Gibney GT, Brown J, Rocconi RP, Jones NL. Too much skin in the game? A paradigm shift in our understanding of vulvar and vaginal melanomas as distinct tumor types compared with cutaneous melanomas. Focused Scientific Plenary. Society of Gynecologic Oncology Annual Meeting, Virtual, March 2021.

Hijazi M*, Capone S*, Mehta A, **In G**. Clinicopathologic Comparison of Basal Cell Carcinoma Between Hispanics and Non-Hispanic Caucasian Patients in Los Angeles County. Poster Presentation at 2021 10th World Congress of Melanoma – 17th EADO Congress.

Fernandez B, Miller M, Sierro T, Shah E, Wong-Michalak S, Haughton R, Rodman J, Mert M, Fong ME, Ganesh S, Han H, **In GK**, Maw TT, Miller K, Smogorzewski M, Hu J, Ngo B, Ahronowitz I. Examining Low Rates of Dermatology Visits in Solid Organ Transplant Recipients. *J Am Acad Dermatol*. Accepted for publication May 20, 2021.

Ebia MI*, **In GK****. Multiple primary malignancies among patients with advanced melanoma. Online Presentation at 2021 ASCO Annual Meeting. *J Clin Oncol*.

Giri U*, Yu X*, Resnick K*, Larsen T*, **In GK****. Venous thromboembolism in patients on checkpoint inhibitors. Online Presentation at 2021 ASCO Annual Meeting. *J Clin Oncol*.

3. Molecular biomarkers for targeted cancer therapy. Whereas previously we determined that EGFR driven lung adenocarcinoma may progress spatio-temporally as a unique pathway from lung metastasis to brain metastases, we next sought to assess the molecular underpinnings of brain metastases in melanoma. We interrogated over 130 melanoma brain tumors in comparison with 745 melanoma primary tumors, which revealed the presence of several epigenetic regulators that were significantly mutated in brain metastases, including those implicating the SWI/SNF pathway, as well as upregulation of the MAPK pathway.

In GK, Mason J, Lin S*, Newton PK, Kuhn P, Nieva J. Development of metastatic brain disease involves progression through lung metastases in *EGFR* mutated non-small cell lung cancer. *Convergent Science Physical Oncology*. 2017 Sep;3(3). PMID: 30283700

Gibney GT, Tang S, Poorman K, Olszanski AJ, Eisenberg B, Mehmi I, Farma JM, **In GK**, Amin A, Rapisuwon S, Vanderwalde A, Atkins MB. Associations of Age, PD-L1 Status, BRAF Mutation and Tumor Mutational Burden (TMB) in Advanced Melanoma. *J Clin Oncol*. DOI: 10.1200/JCO.2018.36.15_suppl.e21609

Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands N, Liu Q, **In G**, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. *Nat Commun*. 2019 Apr 12;10(1):1693. PMID: 30979895

Darabi S, Thomas JS, Demeure MJ, Poorman K, **In GK**, Frankel AE, Vanderwalde A, Olszanski AJ, Farma J, Atkins MB, Grodon M, Eisenberg BL. Oncogenic Gene Fusions in Malignant Melanomas. *Pigment Cell Melanoma Res*. Poster Presentation, 2019 SMR Congress.

Gatalica Z, Vranic S, Kruslin B, Poorman K, Stafford P, Kacerovska D, Senarathne W, Florento E, Contreras E, Leary A, Choi A*, **In GK**. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease. *Cancer Med*. 2020 Jan 3. DOI: 10.1002/cam4.2820. Published online January 3, 2020. PMID: 31899853

In GK, Poorman K, Saul M, O'Day S, Farma JF, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, VanderWalde A. Molecular Profiling of Melanoma Brain Metastases Compared to Primary Cutaneous Melanoma and to Extracranial Metastases. *Oncotarget*. 2020 Aug 18; 11(33):3118-3128. PMID: 32913556

Owsley J, Stein M, Porter J, **In GK**, Salem M, O'Day S, Elliot A, Poorman K, Gibney G, VanderWalde A. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. *Exp Biol Med (Maywood)*. 2020 Oct 5;1535370220959657. PMID: 33019809

Gibney GT, Xiu J, **In GK**, O'Day SJ, Lutzky J, Drabick JJ, VanderWalde A, Poorman K, Korn WM, Atkins MB. Basal Cell Carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies. *J Immunother Cancer*. Poster Presentation, 2020 SITC 35th Annual Meeting.

Ricker C, Amundson E*, Algaze S*, Ciccone M, Dong S*, D'souza A, Felicetti K, Hernandez D, Jayachandran P*, Kang I, Narayanan K, Thomas JS, Tulpule V, Umayam R, Xia B, **In GK****. Assessing somatic and germline variants in cancer patients. Poster Presentation at 2021 ASCO Annual Meeting. *J Clin Oncol*.

Tiu-Lim J, Yin J, Xiu J, Korn WM, Lenz HJ, **In G**, Roussos-Torres ET, Lu J, Spicer D, Ma C, Hoon D, Krill-Jackson E, Heeke A, Sammons S, Isaacs C, Ademuyiwa F, Tan A, Kang IM. Molecular Characterization of the Ras-MAPK Pathway in Metastatic Breast Cancer. Poster Presentation at 2021 ASCO Annual Meeting. *J Clin Oncol*.

Research Support

ONGOING

1UL1TR001855-01	In (PI)	12/05/16-05/30/17	
SC Clinical and Translational Science Institute Evaluating the Genomic Landscape of Melanoma in Hispanics This proposal explores the mutational landscape of acral lentiginous melanoma and other cutaneous melanoma subtypes in patients of Hispanic origin. The proposal seeks to identify: 1) recurrent mutations and 2) copy number alterations, to identify pharmacologically exploitable biological pathways in this disease. Role: Principal Investigator Total Direct Costs			\$3000.00
1UL1TR001855-02	In (PI)	06/06/17-09/06/17	
SC Clinical and Translational Science Institute Enumerating Circulating Tumor Cells as a Prognostic Biomarker for Acral Lentiginous Melanoma The major goals of this project are to survey acral melanoma patients with limited stage I-III disease, to determine whether changes in circulating tumor cell counts may predict time of relapse. Several different CTC platforms will be tested, to identify the most prognostic system, as well as exploring the possibility to use CTC's for molecular profiling to enable targeted therapeutic approach in the event of relapse. Role: Principal Investigator Total Direct Costs			\$3000.00
1UL1TR001855	In (PI)	07/01/19-06/30/20	
SC Clinical and Translational Science Institute Examining the DNA Methylation Landscape of Merkel Cell Carcinoma This project will analyze the DNA methylation profile of patients with localized and metastatic Merkel cell carcinoma, as compared to matched normal tissue, to better understand which pathways may not only impact the development of this disease, but also contribute to metastatic progression. Identified genes/probes of interest will be further studied mechanistically using in vitro assays. Role: Principal Investigator Total Direct Costs			\$3000.00
Dean's Pilot Funding Program	In (PI)	02/03/20-02/03/22	
Keck School of Medicine of USC Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study This prospective clinical trial will assess the safety and feasibility of a program of short-term fasting in combination with PD-1/PD-L1 based immunotherapy in the treatment of patients with advanced malignancies. Correlatives of interest include analyzes of metabolic reprogramming, as well as biomarkers of response to checkpoint blockade, to assess whether fasting may impact the use of cancer immunotherapy. Role: Principal Investigator Total Direct Costs			\$78,544.00
1R37CA256867-01	Miller (PI)	02/01/21-12/30/26	
NIH/NCI Social Health, Activity Behaviors and Quality of Life Among Young Adult Cancer Survivors Social challenges are a major issue for young adult cancer patients (18-39 years old). Impairments in social relationships, referred to as social health, may decrease physical activity after a cancer diagnosis, leading to poorer quality of life after treatment and recovery. This study will investigate the relationships between social health, physical activity, and quality of life to expand our understanding of their interrelations to inform intervention strategies to foster healthy survivorship for young adult cancer patients. Role: Co-Investigator Total Direct Costs			\$496,000.00

COMPLETED

None.

ONGOING CLINICAL TRIALS

R2810-ONC-1915 In (National PI) 06/01/20-06/01/22
Regeneron Pharmaceuticals
Evaluating the PD-1 checkpoint inhibitor, Cemiplimab, as neoadjuvant therapy in high risk localized, locally recurrent, and regionally advanced cutaneous squamous cell carcinoma: a Phase II pilot study (NeoPOWER)
Role: National Principal Investigator
Total Direct Costs **\$1,038,124.00**

NCI 9466 In (Lead USC PI)
NCI/California Cancer Consortium
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumor

NCI 10057 In (Lead USC PI)
NCI/California Cancer Consortium
Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

SWOG S1801 In (Lead USC PI)
Southwest Oncology Group
A phase II randomized study of adjuvant versus neoadjuvant MK-3475 (pembrolizumab) for clinically detectable stage III-IV high risk melanoma

POLARIS In (Lead USC PI)
Array Biopharma
A Phase 2, Open-Label, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAF V600-Mutant Melanoma Brain Metastasis (POLARIS)

ECOG-ACRIN EA6174 In (Lead USC PI)
Eastern Cooperative Oncology Group / American College of Radiology Imaging Network
Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

ALLIANCE A091802 In (Lead USC PI)
Alliance for Clinical Trials in Oncology
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin

IGNYTE In (Lead USC PI)
Replimune
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

DUET-1-02 In (Lead USC PI)
Xencor
A Phase 1b/2 Multiple-Dose Study to Evaluate the Safety and Efficacy of XmAb18087 +/- Pembrolizumab in Subjects with Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

COMPLETED CLINICAL TRIALS

NCI 9922 In (Lead USC PI)
NCI/California Cancer Consortium
Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance

SWOG S1512 In (Lead USC PI)
Southwest Oncology Group
Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma

SWOG S1607 In (Lead USC PI)
Southwest Oncology Group
Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

IMspire170 In (Lead USC PI)
Genentech Inc
A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

ILLUMINATE-301 In (Lead USC PI)
Idera Pharmaceuticals
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma